US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Maze Therapeutics

12.93

-0.4100-3.07%

Post-market: 12.90-0.0300-0.23%19:33 EDT

Volume:67.77K

Turnover:884.71K

Market Cap:566.30M

PE:38.54

High:13.60

Open:13.48

Low:12.78

Close:13.34

Loading ...

Overview Company News Filings

Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target

MT Newswires Live

Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target

MT Newswires Live

JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target

MT Newswires Live

Maze Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $30

THOMSON REUTERS

Maze Therapeutics Initiated at Overweight by JP Morgan

Maze Therapeutics initiated with a Buy at TD Cowen

Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics

Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829

Maze Therapeutics initiated with an Overweight at JPMorgan

Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market

Maze Therapeutics initiated with a Buy at Guggenheim

Maze Therapeutics Inc - Interim Data Readout Expected in Q1 2026

THOMSON REUTERS

Maze Therapeutics Doses First Patient in Phase 2 Horizon Clinical Trial Evaluating Mze829 as a Potential Treatment for Apol1 Kidney Disease

THOMSON REUTERS

Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut

Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut

Stock Track | Maze Therapeutics Soars 6.25% After Pricing Upsized $140 Million IPO at $16 Per Share

Maze Therapeutics Shares Open at $16.12 in Nasdaq Debut VS $16 IPO Price

THOMSON REUTERS

Oil company Infinity Natural Resources debuts IPO amid deregulation push

Maze Therapeutics Prices Upsized IPO at $16 Per Share

MT Newswires Live

Biotech firm Maze Therapeutics raises $140 million in US IPO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MAZE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":12.93,"timestamp":1749240000000,"preClose":13.34,"halted":0,"volume":67773,"hourTrading":{"tag":"盘后","latestPrice":12.9,"preClose":12.93,"latestTime":"19:33 EDT","volume":15577,"amount":202194.06,"timestamp":1749252819977},"delay":0,"floatShares":16929527,"shares":43797166,"eps":0.33546,"marketStatus":"Not Yet Opened","change":-0.41,"latestTime":"06-06 16:00:00 EDT","open":13.48,"high":13.6,"low":12.78,"amount":884714.570478,"amplitude":0.061469,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.33546,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":0,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":13.34,"postHourTrading":{"tag":"盘后","latestPrice":12.9,"preClose":12.93,"latestTime":"19:33 EDT","volume":15577,"amount":202194.06,"timestamp":1749252819977},"volumeRatio":0.47257100928405693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":16929527,"roa":"11.44%","roe":"34.38%","lyrEps":1.421062,"volumeRatio":0.47257100928405693,"shares":43797166,"dividePrice":0,"high":13.6,"amplitude":0.061469,"preClose":13.34,"low":12.78,"week52Low":6.71,"pbRate":"1.94","psRate":"3.38","week52High":17,"institutionHeld":0,"latestPrice":12.93,"eps":0.33546,"divideRate":0,"volume":67773,"delay":0,"ttmEps":0.33546,"open":13.48,"prevYearClose":16,"prevWeekClose":10.01,"prevMonthClose":10.01,"prevQuarterClose":11.01,"fiveDayClose":10.01,"twentyDayClose":10.02,"sixtyDayClose":11.3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514067327","title":"Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067327?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482514,"startTime":"0","endTime":"0","summary":"Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514067340","title":"Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067340?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482507,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates Maze Therapeutics at Outperform With $28 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514067373","title":"JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067373?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:21","pubTimestamp":1740482493,"startTime":"0","endTime":"0","summary":"JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2514064120","title":"Maze Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064120?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:58","pubTimestamp":1740481104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG03V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2514199064","title":"Maze Therapeutics Initiated at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2514199064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514199064?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:49","pubTimestamp":1740480540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 05:49 ET (10:49 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2514064852","title":"Maze Therapeutics initiated with a Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064852?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:41","pubTimestamp":1740480066,"startTime":"0","endTime":"0","summary":"TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, could...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","BK4127","TD","BK4007","COWN","BK4207","BK4585","MAZE"],"gpt_icon":0},{"id":"2514064866","title":"Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064866","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064866?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:35","pubTimestamp":1740479737,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren. Tyler Van Buren has given his Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-drug-candidates-and-market-potential-drive-buy-rating-for-maze-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-drug-candidates-and-market-potential-drive-buy-rating-for-maze-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2514690200","title":"Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829","url":"https://stock-news.laohu8.com/highlight/detail?id=2514690200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514690200?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:15","pubTimestamp":1740478550,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by J.P. Morgan analyst, Anupam Rama. Anupam Rama has given his Buy rating d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-inc-buy-rating-backed-by-promising-pipeline-and-lead-asset-mze829?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-inc-buy-rating-backed-by-promising-pipeline-and-lead-asset-mze829?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2514069091","title":"Maze Therapeutics initiated with an Overweight at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2514069091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514069091?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:11","pubTimestamp":1740478271,"startTime":"0","endTime":"0","summary":"JPMorgan initiated coverage of Maze Therapeutics (MAZE) with an Overweight rating and $30 price target The company’s Compass platform has produced ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-an-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-an-overweight-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2514069076","title":"Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2514069076","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514069076?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:08","pubTimestamp":1740478092,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by Guggenheim analyst, Debjit Chattopadhyay. Debjit Chattopadhyay has given...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-strategic-positioning-and-growth-potential-in-genetic-disorders-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-strategic-positioning-and-growth-potential-in-genetic-disorders-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2514660070","title":"Maze Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2514660070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514660070?lang=en_us&edition=fundamental","pubTime":"2025-02-25 18:01","pubTimestamp":1740477705,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Debjit Chattopadhyay initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $19 price target The company has advan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2509748065","title":"Maze Therapeutics Inc - Interim Data Readout Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2509748065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509748065?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nTUA9TG5WR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE"],"gpt_icon":0},{"id":"2509474806","title":"Maze Therapeutics Doses First Patient in Phase 2 Horizon Clinical Trial Evaluating Mze829 as a Potential Treatment for Apol1 Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2509474806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509474806?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nTUA9TG5WR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE"],"gpt_icon":0},{"id":"2508099804","title":"Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2508099804","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508099804?lang=en_us&edition=fundamental","pubTime":"2025-02-01 01:38","pubTimestamp":1738345112,"startTime":"0","endTime":"0","summary":"UPDATE 3-Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debutAdds analyst comments in paragraph 11By Ateev Bhandari","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OR1C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ90724238.SGD","SG9999002950.SGD","VG","BK4023","SG9999001069.SGD","SG9999001051.SGD","LU0541501648.USD","MAZE","BK1603","LU0173614495.USD","LU1166156734.SGD","00288","LU0287142896.SGD","LU0274383008.USD","SFD","LU0702159699.USD","LU0541502299.USD","BK1543","BK1521","BK1237","SG9999001226.SGD"],"gpt_icon":0},{"id":"2508998165","title":"Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2508998165","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508998165?lang=en_us&edition=fundamental","pubTime":"2025-02-01 01:25","pubTimestamp":1738344329,"startTime":"0","endTime":"0","summary":"Maze Therapeutics valued at $690.4 million as shares rise marginally in market debutJan 31  - Shares of Maze Therapeutics MAZE.O rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OR1BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"1136600250","title":"Stock Track | Maze Therapeutics Soars 6.25% After Pricing Upsized $140 Million IPO at $16 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1136600250","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136600250?lang=en_us&edition=fundamental","pubTime":"2025-02-01 01:22","pubTimestamp":1738344145,"startTime":"0","endTime":"0","summary":"Shares of Maze Therapeutics  surged 6.25% in Friday's trading session, following the company's successful pricing of its upsized initial public offering  a day earlier.On Thursday evening, Maze Therapeutics announced that it had priced its IPO of approximately 8.8 million shares at $16 per share, raising gross proceeds of $140 million. The offering was upsized from the company's initial plans, indicating strong investor demand.In addition to the 8.8 million shares sold in the IPO, Maze Therapeut","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Maze Therapeutics Soars 6.25% After Pricing Upsized $140 Million IPO at $16 Per Share","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MAZE"],"gpt_icon":0},{"id":"2508986669","title":"Maze Therapeutics Shares Open at $16.12 in Nasdaq Debut VS $16 IPO Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2508986669","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508986669?lang=en_us&edition=fundamental","pubTime":"2025-02-01 01:20","pubTimestamp":1738344033,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nFWN3OR2E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE"],"gpt_icon":0},{"id":"2507961888","title":"Oil company Infinity Natural Resources debuts IPO amid deregulation push","url":"https://stock-news.laohu8.com/highlight/detail?id=2507961888","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507961888?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:20","pubTimestamp":1738336800,"startTime":"0","endTime":"0","summary":"Company prices above midrange as the largest of a batch of initial public offerings on Friday. Infinity Natural Resources Inc. priced its initial public offering above the midpoint of its range in a sign of a strong stock-market debut for the oil and gas producer, which operates in Ohio and Pennsylvania.The IPO comes amid a deregulatory push in the energy sector by President Donald Trump, who repeated the \"drill, baby, drill\" slogan in his inaugural address.Earlier this week, Sean Duffy, the newly sworn-in Transportation secretary, ordered a review of fuel-economy standards laid out by the Biden administration.Infinity Natural Resources  priced 13.25 million shares at $20 for proceeds of $265 million. The IPO priced toward the upper end of its range of $18 to $21 in a sign of healthy demand.Infinity Natural Resources is the largest of a handful of IPOs on Friday.Maze Therapeutics Inc.  priced 8.75 million shares at $16 a share for proceeds of $140 million. The stock priced at the midpo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR","MAZE","BBNX","INR"],"gpt_icon":0},{"id":"2507393076","title":"Maze Therapeutics Prices Upsized IPO at $16 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2507393076","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507393076?lang=en_us&edition=fundamental","pubTime":"2025-01-31 17:36","pubTimestamp":1738316172,"startTime":"0","endTime":"0","summary":"Maze Therapeutics  said late Thursday it priced its upsized initial public offering of about 8.8 million shares at $16 per share for gross proceeds of $140 million.In addition, Maze Therapeutics said it has granted the underwriters a 30-day option to purchase up to an additional 1.3 million shares of common stock at the initial public offering price, less underwriting discounts and commissions.The shares are expected to begin trading on the Nasdaq on Friday under the symbol 'MAZE.'The offering is expected to close on Monday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2507886039","title":"Biotech firm Maze Therapeutics raises $140 million in US IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507886039","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507886039?lang=en_us&edition=fundamental","pubTime":"2025-01-31 09:01","pubTimestamp":1738285284,"startTime":"0","endTime":"0","summary":"UPDATE 2-Biotech firm Maze Therapeutics raises $140 million in US IPOAdds valuation of the company in paragraph 3; background in paragraph 12. Jan 30  - Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech listing this year.Maze priced the offering at $16 per share, within its indicated range of $15 to $17.The IPO valued the California-based company at approximately $685 million, ahead of its market debut, which comes after lackluster first-day performances from other high-profile firms such as Venture Global VG.N and Smithfield Foods SFD.O in recent days.Investors in Maze include healthcare venture firms ARCH Venture and Third Rock Ventures, along with Alphabet's GOOGL.O venture capital arm GV.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250131:nL3N3OR01T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999000418.SGD","BK4576","GOOGL","LU1935042215.USD","LU1267930227.SGD","LU1116320901.HKD","BK4077","LU0154236417.USD","LU0061474960.USD","BK4579","LU0792757196.USD","LU1791710582.SGD","LU1629891620.HKD","LU1633808545.USD","LU1046421795.USD","LU0823421416.USD","IE00BQXX3D17.EUR","IE00BK4W5M84.HKD","LU0203345920.USD","LU0345769128.USD","LU1674673428.USD","LU0048573561.USD","LU0029864427.USD","LU2191332357.HKD","LU0107464264.USD","SG9999014906.USD","SGXZ31699556.SGD","LU2054465674.USD","LU0323591593.USD","LU0957791311.USD","LU1064131342.USD","LU1868837300.USD","BK4561","LU0187121727.USD","LU1823568750.SGD","LU0158827948.USD","BK4533","LU1496350502.SGD","LU2264538146.SGD","SGXZ81514606.USD","LU1303367103.USD","LU0061474705.USD","LU2357305700.SGD","IE0004086264.USD","LU0130102774.USD","MAZE","LU0426417589.USD","LU0106261372.USD","LU1059921491.USD","LU2275660780.HKD"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"MAZE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.15},{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1740542400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2025-06-06","current":11.248853,"percent":0.931818,"low":6.347498,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"high":12.681398,"avg":8.927521,"sd":1.379451,"marketCap":584254194},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194}],"updateTime":1749446298687}}}